AU2019243289B2 - Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer - Google Patents

Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer Download PDF

Info

Publication number
AU2019243289B2
AU2019243289B2 AU2019243289A AU2019243289A AU2019243289B2 AU 2019243289 B2 AU2019243289 B2 AU 2019243289B2 AU 2019243289 A AU2019243289 A AU 2019243289A AU 2019243289 A AU2019243289 A AU 2019243289A AU 2019243289 B2 AU2019243289 B2 AU 2019243289B2
Authority
AU
Australia
Prior art keywords
alkyl
independently selected
compound
aryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019243289A
Other languages
English (en)
Other versions
AU2019243289A1 (en
Inventor
Zenon D. Konteatis
Mingzong Li
Peng Liu
Guangning MA
Matthew MEDEIROS
Janeta Popovici-Muller
Samuel K. REZNIK
Zhihua Sui
Jeremy M. Travins
Shubao ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2019243289A1 publication Critical patent/AU2019243289A1/en
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2019243289B2 publication Critical patent/AU2019243289B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2019243289A 2018-03-30 2019-03-28 Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer Active AU2019243289B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
CNPCT/CN2018/081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (2)

Publication Number Publication Date
AU2019243289A1 AU2019243289A1 (en) 2020-09-24
AU2019243289B2 true AU2019243289B2 (en) 2023-01-12

Family

ID=67439309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019243289A Active AU2019243289B2 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer

Country Status (21)

Country Link
US (1) US11524960B2 (enExample)
EP (1) EP3774805B1 (enExample)
JP (2) JP7350005B2 (enExample)
KR (1) KR102736073B1 (enExample)
CN (1) CN111936499B (enExample)
AR (1) AR115326A1 (enExample)
AU (1) AU2019243289B2 (enExample)
BR (1) BR112020020104A2 (enExample)
CA (1) CA3094476C (enExample)
EA (1) EA202092320A1 (enExample)
ES (1) ES2973114T3 (enExample)
HU (1) HUE066282T2 (enExample)
IL (1) IL277665B2 (enExample)
MA (1) MA52232A (enExample)
MX (1) MX2020010005A (enExample)
PH (1) PH12020551507A1 (enExample)
PL (1) PL3774805T3 (enExample)
SG (1) SG11202009195WA (enExample)
TW (1) TWI719437B (enExample)
UA (1) UA127059C2 (enExample)
WO (1) WO2019191470A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US12077534B2 (en) * 2018-12-27 2024-09-03 Les Laboratoires Servier Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
AU2019414446A1 (en) * 2018-12-27 2021-07-15 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
AR119046A1 (es) * 2019-05-31 2021-11-17 Agios Pharmaceuticals Inc Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040B1 (en) * 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
TW202214630A (zh) * 2020-09-12 2022-04-16 大陸商成都倍特藥業股份有限公司 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022143864A1 (zh) 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
JP7721686B2 (ja) * 2021-06-02 2025-08-12 南京正大天晴制薬有限公司 メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
CN118742550B (zh) * 2022-03-11 2025-09-05 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
AU2023299635A1 (en) 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
EP4582423A1 (en) 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4729518A1 (en) * 2023-06-14 2026-04-22 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045071A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP5993742B2 (ja) 2009-10-29 2016-09-14 ジェノスコ キナーゼ阻害剤
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045071A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Also Published As

Publication number Publication date
JP7350005B2 (ja) 2023-09-25
KR20200138769A (ko) 2020-12-10
PL3774805T3 (pl) 2024-05-06
HUE066282T2 (hu) 2024-07-28
AU2019243289A1 (en) 2020-09-24
WO2019191470A1 (en) 2019-10-03
IL277665A (en) 2020-11-30
JP2023101762A (ja) 2023-07-21
JP2021519783A (ja) 2021-08-12
PH12020551507A1 (en) 2021-09-13
TW201946629A (zh) 2019-12-16
IL277665B2 (en) 2023-06-01
KR102736073B1 (ko) 2024-12-02
MA52232A (fr) 2021-02-17
EP3774805A1 (en) 2021-02-17
US11524960B2 (en) 2022-12-13
SG11202009195WA (en) 2020-10-29
EP3774805B1 (en) 2024-01-10
US20210115045A1 (en) 2021-04-22
CN111936499A (zh) 2020-11-13
NZ767697A (en) 2025-02-28
MX2020010005A (es) 2020-10-14
WO2019191470A8 (en) 2019-12-12
AR115326A1 (es) 2020-12-23
BR112020020104A2 (pt) 2021-01-26
CN111936499B (zh) 2023-09-19
CA3094476C (en) 2025-05-06
ES2973114T3 (es) 2024-06-18
CA3094476A1 (en) 2019-10-03
EA202092320A1 (ru) 2021-03-09
UA127059C2 (uk) 2023-03-29
TWI719437B (zh) 2021-02-21

Similar Documents

Publication Publication Date Title
EP3774805B1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
AU2019416349B2 (en) Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
US10570139B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
CA3034705C (en) Inhibitors of cellular metabolic processes
KR20230167071A (ko) 유비퀴틴-특이적 프로테아제 1 (usp1)의 억제
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP2252616B1 (en) Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
KR20230049580A (ko) 트리아졸론 화합물
TW202529739A (zh) Parg之抑制劑
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA041815B1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)